AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27041257 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and acetaminophen (n = 38)
Number of subjects: 70
Study 27041257 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen only (n = 32)
Number of subjects: 70
Study 24508292 — intervention group
Group type: EXPERIMENTAL
Intervention: Appearance-based video education
Number of subjects: 50
Study 24508292 — intervention group
Group type: COMPARATOR
Intervention: Health-based video education
Number of subjects: 50
Study 22520863 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) for AECOPD administered twice daily over 7 to 21 days, followed by TCM for AECOPD-RW over 28 days.
Number of subjects: 364
Study 22520863 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo) receiving medication according to assigned group.
Number of subjects: 364
Study 22520863 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM for AECOPD and AECOPD-RW.
Number of subjects: 364
Study 20150290 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin
Number of subjects: 1229
Study 20150290 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin
Number of subjects: 1229
Study 18560257 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 28
Study 18560257 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 28
Study 16421496 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic portal imaging (EPI) with online field realignment
Number of subjects: 14
Study 16421496 — intervention group
Group type: COMPARATOR
Intervention: Control group (no online beam realignment)
Number of subjects: 14
Study 12046488 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer containing 10% urea and 4% lactic acid
Number of subjects: 40
Study 12046488 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream (control)
Number of subjects: 40
Study 10452633 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg daily)
Number of subjects: 149
Study 10452633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 10452633 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 149
Study 7792376 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery preparation
Number of subjects: 51
Study 7792376 — intervention group
Group type: COMPARATOR
Intervention: Background information about the hospital (Control)
Number of subjects: 51
Study 2198918 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of oral mifepristone
Number of subjects: 20
Study 2198918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 318958 — intervention group
Group type: EXPERIMENTAL
Intervention: Ammonium fluoride rinse (1,000 parts/10(6) solution at pH 4.4)
Number of subjects: 200
Study 318958 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride rinse (1,000 parts/10(6) solution at pH 4.4)
Number of subjects: 200
Study 318958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 30709391 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment as usual plus activation therapy (AT)
Number of subjects: 0
Study 30709391 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 28911934 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest (DNG) 2 mg/d, orally for 16 weeks
Number of subjects: 67
Study 28911934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 25529904 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (TNF antagonist)
Number of subjects: 36
Study 25529904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 23651847 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training for 16 weeks
Number of subjects: 13
Study 23651847 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 13
Study 21412057 — intervention group
Group type: EXPERIMENTAL
Intervention: EVG/COBI/FTC/TDF
Number of subjects: 71
Study 21412057 — intervention group
Group type: COMPARATOR
Intervention: EFV/FTC/TDF
Number of subjects: 71
Study 19469829 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg
Number of subjects: 404
Study 19469829 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg
Number of subjects: 404
Study 19469829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study 17424753 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 60
Study 17424753 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 60
Study 17424753 — intervention group
Group type: COMPARATOR
Intervention: Both drugs (1.5 x ED95)
Number of subjects: 60
Study 10807113 — intervention group
Group type: EXPERIMENTAL
Intervention: Subantimicrobial dose doxycycline (SDD) 20 mg bid for 9 months
Number of subjects: 190
Study 10807113 — intervention group
Group type: COMPARATOR
Intervention: Placebo bid for 9 months
Number of subjects: 190
Study 8634730 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (AIDS-risk reduction intervention)
Number of subjects: 383
Study 8634730 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 383
Study 1996758 — intervention group
Group type: EXPERIMENTAL
Intervention: Air alone with spontaneous respiration
Number of subjects: 36
Study 1996758 — intervention group
Group type: EXPERIMENTAL
Intervention: Air supplemented with 1 or 4 litres/minute of oxygen
Number of subjects: 36
Study 1996758 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial ventilation with air alone
Number of subjects: 36
Study 1996758 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous respiration with at least 0.5 litres/minute of oxygen
Number of subjects: 36
Study 1996758 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent positive pressure ventilation
Number of subjects: 36
Study 1996758 — intervention group
Group type: EXPERIMENTAL
Intervention: Air anaesthesia with spontaneous ventilation
Number of subjects: 36
Study 6337671 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemorrhoidectomy
Number of subjects: 112
Study 6337671 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal anal dilation
Number of subjects: 112
Study 6337671 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 112
Study 6337671 — intervention group
Group type: COMPARATOR
Intervention: Elastic band ligation
Number of subjects: 112
Study 30557850 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg daily
Number of subjects: 81
Study 30557850 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 150 mg daily
Number of subjects: 81
Study 29684316 — intervention group
Group type: EXPERIMENTAL
Intervention: Active CPAP
Number of subjects: 138
Study 29684316 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 138
Study 29684316 — intervention group
Group type: EXPERIMENTAL
Intervention: White race
Number of subjects: 138
Study 29684316 — intervention group
Group type: EXPERIMENTAL
Intervention: Week 1 adherence
Number of subjects: 138
Study 27698558 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined physical and cognitive training (aerobic and resistance training + dual-task training)
Number of subjects: 76
Study 27698558 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic-strength condition
Number of subjects: 76
Study 27698558 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task (DT) training
Number of subjects: 76
Study 27698558 — intervention group
Group type: COMPARATOR
Intervention: Stretching and toning exercises (active control)
Number of subjects: 76
Study 25315126 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 1.5 mg·ml(‐1), 1 ml·kg(‐1) mixed with 50 mg of magnesium (Group RM)
Number of subjects: 80
Study 25315126 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 1.5 mg·ml(‐1), 1 ml·kg(‐1) (Group R)
Number of subjects: 80
Study 22570185 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation training
Number of subjects: 90
Study 22570185 — intervention group
Group type: COMPARATOR
Intervention: Standard single-dose methotrexate treatment
Number of subjects: 90
Study 20026785 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin (1500 mg/d)
Number of subjects: 33
Study 20026785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 20026785 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL from healthy subjects (n=10)
Number of subjects: 33
Study 17850370 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate biopsy
Number of subjects: 40
Study 17850370 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 40
Study 17850370 — intervention group
Group type: COMPARATOR
Intervention: Biopsy status (positive or negative)
Number of subjects: 40
Study 16602327 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (group A)
Number of subjects: 31
Study 16602327 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oral antihistamine (cetirizine) treatment (group B)
Number of subjects: 31
Study 16602327 — intervention group
Group type: COMPARATOR
Intervention: Oral antihistamine (cetirizine) on demand (group C)
Number of subjects: 31
Study 11929078 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg/day)
Number of subjects: 14
Study 11929078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 10432474 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine plus interpersonal psychotherapy (IPT + FLU)
Number of subjects: 23
Study 10432474 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal psychotherapy alone (IPT)
Number of subjects: 23
Study 7569269 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (HMG CoA reductase inhibitor), dosage and duration not specified
Number of subjects: 0
Study 2404502 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release felodipine tablets once daily
Number of subjects: 147
Study 2404502 — intervention group
Group type: COMPARATOR
Intervention: Conventional felodipine tablets twice daily
Number of subjects: 147
Study 31246662 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticocancellous particulate allograft (Mineross) mixed with autogenous bone chips (70:30)
Number of subjects: 14
Study 31246662 — intervention group
Group type: COMPARATOR
Intervention: DBM (Optecure‐CCC)
Number of subjects: 14
Study 30379826 — intervention group
Group type: EXPERIMENTAL
Intervention: Evocalcet 0.5 mg/day
Number of subjects: 152
Study 30379826 — intervention group
Group type: EXPERIMENTAL
Intervention: Evocalcet 1 mg/day
Number of subjects: 152
Study 30379826 — intervention group
Group type: EXPERIMENTAL
Intervention: Evocalcet 2 mg/day
Number of subjects: 152
Study 30379826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 30379826 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet 25 mg/day
Number of subjects: 152
Study 27627194 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose 175 mg omarigliptin
Number of subjects: 60
Study 27627194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 27627194 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose 25 mg omarigliptin
Number of subjects: 60
Study 27627194 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose 400 mg moxifloxacin
Number of subjects: 60
Study 27627194 — intervention group
Group type: COMPARATOR
Intervention: Placebo (days 1 and 2)
Number of subjects: 60
Study 24955738 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine system for grading retinal images by non-physician readers
Number of subjects: 2000
Study 24955738 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic examination (DE) performed by experienced ophthalmologists
Number of subjects: 2000
Study 22968888 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician assessment-based adjustment
Number of subjects: 342
Study 22968888 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-based (exhaled nitric oxide) adjustment
Number of subjects: 342
Study 22968888 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-based adjustment
Number of subjects: 342
Study 20335355 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 60
Study 20335355 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 60
Study 17617525 — intervention group
Group type: EXPERIMENTAL
Intervention: Fertility‐sparing surgery
Number of subjects: 0
Study 17617525 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy (bleomycin, etoposide, cisplatin)
Number of subjects: 0
Study 17617525 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum cytoreductive surgery
Number of subjects: 0
Study 17617525 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance strategy
Number of subjects: 0
Study 17617525 — intervention group
Group type: EXPERIMENTAL
Intervention: Second‐look surgery
Number of subjects: 0
Study 16195045 — intervention group
Group type: EXPERIMENTAL
Intervention: Jump condition
Number of subjects: 7
Study 16195045 — intervention group
Group type: EXPERIMENTAL
Intervention: Run-up plus jump condition
Number of subjects: 7
Study 16195045 — intervention group
Group type: EXPERIMENTAL
Intervention: Run-up condition
Number of subjects: 7
Study 12454315 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (e.g., paclitaxel/trastuzumab or capecitabine/docetaxel)
Number of subjects: 0
Study 12454315 — intervention group
Group type: COMPARATOR
Intervention: Sequential therapy
Number of subjects: 0
Study 10361111 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate serum hyaluronan (HYA) values (10 to 120 micrograms/L)
Number of subjects: 386
Study 10361111 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormally low HYA values (0 to 9 micrograms/L)
Number of subjects: 386
Study 10361111 — intervention group
Group type: EXPERIMENTAL
Intervention: High HYA values (>120 micrograms/L)
Number of subjects: 386
Study 7595711 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL‐6 at 10.0 micrograms/kg/d
Number of subjects: 19
Study 7595711 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL‐6 at 20.0 micrograms/kg/d
Number of subjects: 19
Study 7595711 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL‐6 at various doses
Number of subjects: 19
Study 7595711 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL‐6 at 10.0 and 20.0 micrograms/kg/d
Number of subjects: 19
Study 7595711 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL‐6
Number of subjects: 19
Study 2405628 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose warfarin (average daily dose of 4.6 mg)
Number of subjects: 0
Study 2405628 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 0
Study 2405628 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of low-dose warfarin and low-dose aspirin
Number of subjects: 0
Study 6966720 — intervention group
Group type: EXPERIMENTAL
Intervention: Travenol microporous polypropylene membrane oxygenator
Number of subjects: 64
Study 6966720 — intervention group
Group type: COMPARATOR
Intervention: Bentley Q-100 bubble oxygenator
Number of subjects: 64
Study 31722381 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 82
Study 31722381 — intervention group
Group type: COMPARATOR
Intervention: Conventional dual‐chamber pacing with algorithms for right ventricular pacing avoidance (DDD‐VPA)
Number of subjects: 82
Study 31104819 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Hydroxide (CH)
Number of subjects: 64
Study 31104819 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 64
Study 31104819 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 64
Study 27161806 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured glomerular filtration rate (GFR) decline
Number of subjects: 101
Study 25873338 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative format of Summary-of-Findings tables (Table A)
Number of subjects: 0
Study 25873338 — intervention group
Group type: COMPARATOR
Intervention: Current standard format of Summary-of-Findings tables (Table C)
Number of subjects: 0
Study 23515127 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation (IF) using 2 cannulated screws
Number of subjects: 60
Study 23515127 — intervention group
Group type: COMPARATOR
Intervention: Cemented hemiarthroplasty (HA) using a cemented Exeter unipolar arthroplasty
Number of subjects: 60
Study 21075644 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training with web-enabled video feedback and a Question Prompt Sheet (QPS)
Number of subjects: 210
Study 21075644 — intervention group
Group type: EXPERIMENTAL
Intervention: Question Prompt Sheet (QPS)
Number of subjects: 210
Study 21075644 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (communication skills training)
Number of subjects: 210
Study 21075644 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 210
Study 19226611 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy and hypnosis (CBTH)
Number of subjects: 40
Study 18004255 — intervention group
Group type: EXPERIMENTAL
Intervention: TIKLO (250 mg, BID)
Number of subjects: 63
Study 18004255 — intervention group
Group type: COMPARATOR
Intervention: Thrombo ASS (100 mg, QD)
Number of subjects: 63
Study 15209688 — intervention group
Group type: EXPERIMENTAL
Intervention: rizatriptan 10 mg
Number of subjects: 112
Study 15209688 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 112
Study 11239527 — intervention group
Group type: EXPERIMENTAL
Intervention: HOST-selected live spermatozoa
Number of subjects: 30
Study 11239527 — intervention group
Group type: COMPARATOR
Intervention: No-HOST (nonselected sperm)
Number of subjects: 30
Study 9740439 — intervention group
Group type: COMPARATOR
Intervention: Standard swim-up semen preparation (Group A)
Number of subjects: 121
Study 9740439 — intervention group
Group type: EXPERIMENTAL
Intervention: Swim-up followed by test yolk buffer incubation (Group B)
Number of subjects: 121
Study 9740439 — intervention group
Group type: COMPARATOR
Intervention: Standard swim-up (male factor group)
Number of subjects: 121
Study 9740439 — intervention group
Group type: EXPERIMENTAL
Intervention: Swim-up and TYB incubation (male factor group)
Number of subjects: 121
Study 9740439 — intervention group
Group type: COMPARATOR
Intervention: Standard swim-up (unexplained infertility group)
Number of subjects: 121
Study 9740439 — intervention group
Group type: EXPERIMENTAL
Intervention: Swim-up and TYB incubation (unexplained infertility group)
Number of subjects: 121
Study 7914611 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/day amiodarone
Number of subjects: 516
Study 7914611 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 516
Study 3054011 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin (broad-spectrum antibiotic) given as three perioperative doses, each 6 hours apart.
Number of subjects: 417
Study 3054011 — intervention group
Group type: COMPARATOR
Intervention: Placebo given as three perioperative doses, each 6 hours apart.
Number of subjects: 417
Study 30677780 — intervention group
Group type: EXPERIMENTAL
Intervention: Group intervention consisting of eight sessions led by a psychotherapist and a former head and neck cancer patient (peer)
Number of subjects: 113
Study 30677780 — intervention group
Group type: COMPARATOR
Intervention: Socio-legal counselling
Number of subjects: 113
Study 29231471 — intervention group
Group type: EXPERIMENTAL
Intervention: Penetration acupuncture at Baxie (EX‐UE 9) combined with rehabilitation
Number of subjects: 60
Study 29231471 — intervention group
Group type: COMPARATOR
Intervention: Simple rehabilitation
Number of subjects: 60
Study 25225715 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBV)
Number of subjects: 36
Study 25225715 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 23510493 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg for 6 weeks, then increased to 10 mg till week 12, then hydrochlorothiazide 25 mg added
Number of subjects: 90
Study 23510493 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg till week 6, then amlodipine 5‐10 mg added
Number of subjects: 90
Study 23510493 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5‐10 mg + hydrochlorothiazide 25 mg
Number of subjects: 90
Study 21330846 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotomous checklist for performance rating
Number of subjects: 0
Study 21330846 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Performance Assessment Tool (GPAT)
Number of subjects: 0
Study 21330846 — intervention group
Group type: EXPERIMENTAL
Intervention: Both instruments (checklist and GPAT)
Number of subjects: 0
Study 19060022 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.3 mg/kg twice daily)
Number of subjects: 40
Study 16861943 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab + Mycophenolate mofetil + Prednisolone (Dac-group)
Number of subjects: 54
Study 16861943 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A + Mycophenolate mofetil + Prednisolone (CsA-group)
Number of subjects: 54
Study 14748819 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate high-calorie diet
Number of subjects: 0
Study 14748819 — intervention group
Group type: COMPARATOR
Intervention: High-fat high-calorie diet
Number of subjects: 0
Study 14748819 — intervention group
Group type: COMPARATOR
Intervention: Balanced normal calorie diet
Number of subjects: 0
Study 11690571 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma fibrinogen levels (baseline <314 mg/dL)
Number of subjects: 176
Study 11690571 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma fibrinogen levels (314 to 373 mg/dL)
Number of subjects: 176
Study 11690571 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma fibrinogen levels (>373 mg/dL)
Number of subjects: 176
Study 11690571 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper tertile of fibrinogen levels (>373 mg/dL)
Number of subjects: 176
Study 11690571 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in fibrinogen from baseline
Number of subjects: 176